GAVISCON ADVANCE

Posology Adults and children 12 years and over:

One to two tablets after meals and at bedtime.

Children under 12 years:

Should be given only on medical advice.

Duration of treatment:

If symptoms do no improve after seven days, the clinical situation should be reviewed.

Special patient groups:

Elderly: No dose modifications necessary for this age group. 4). Method of administration For oral administration, after being thoroughly chewed.

Adverse reactions have been ranked under headings of frequency using the following convention: very common (1/10), common (1/100 and <1/10), uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (<1/10,000) and not known (cannot be estimated from the available data).

System Organ Class Frequency Adverse Event Gastrointestinal Disorders Uncommon Diarrhoea, nausea, vomiting. Immune System Disorders Very rare Anaphylactic and anaphylactoid reactions. Hypersensitivity reactions such as urticaria. Respiratory, Thoracic and Mediastinal Disorders Very rare Respiratory effects such as bronchospasm.

Reporting of Suspected Adverse Reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

If symptoms do not improve after seven days, the clinical situation should be reviewed. 0 mmol (40 mg) of calcium. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.

7% of the WHO recommended maximum daily intake for sodium. 28 % of the WHO recommended maximum daily intake for sodium. This is based on a two tablet dose taken four times per day. g. in some cases of congestive cardiac failure and renal impairment) or when taking drugs which can increase plasma potassium levels.

43 mg) potassium per tablet. To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet. 5 mg aspartame in each tablet. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.

Due to its aspartame content this product should not be given to patients with phenylketonuria May cause central nervous system depression in the presence of renal insufficiency and should not be used in patients with renal failure.

2.

1.